Radiation Oncology Branch, National Cancer Institute, 10 Center Drive-MSC 1002, Building 10, B3B69B, Bethesda, MD, 20892, USA.
Sci Rep. 2022 Mar 8;12(1):4059. doi: 10.1038/s41598-022-07928-4.
Increased ribosome biogenesis is a distinguishing feature of cancer cells, and small molecule inhibitors of ribosome biogenesis are currently in clinical trials as single agent therapy. It has been previously shown that inhibiting ribosome biogenesis through the inhibition of nuclear export of ribosomal subunits sensitizes tumor cells to radiotherapy. In this study, the radiosensitizing potential of CX-5461, a small molecule inhibitor of RNA polymerase I, was tested. Radiosensitization was measured by clonogenic survival assay in a panel of four tumor cell lines derived from three different tumor types commonly treated with radiation. 50 nM CX-5461 radiosensitized PANC-1, U251, HeLa, and PSN1 cells with dose enhancement factors in the range of 1.2-1.3. However, 50 nM CX-5461 was not sufficient to inhibit 45S transcription alone or in combination with radiation. The mechanism of cell death with the combination of CX-5461 and radiation occurred through mitotic catastrophe and not apoptosis. CX-5461 inhibited the repair and/or enhanced the initial levels of radiation-induced DNA double strand breaks. Understanding the mechanism of CX-5461-induced radiosensitization should be of value in the potential application of the CX-5461/radiotherapy combination in cancer treatment.
核糖体生物发生的增加是癌细胞的一个显著特征,目前正在临床试验中作为单一药物疗法来抑制核糖体生物发生的小分子抑制剂。先前已经表明,通过抑制核输出核糖体亚基来抑制核糖体生物发生可以使肿瘤细胞对放射治疗敏感。在这项研究中,测试了 RNA 聚合酶 I 的小分子抑制剂 CX-5461 的放射增敏潜力。通过来自三种不同肿瘤类型的四种肿瘤细胞系的克隆形成存活测定来测量放射增敏作用,这些肿瘤细胞系通常接受放射治疗。50 nM 的 CX-5461 使 PANC-1、U251、HeLa 和 PSN1 细胞的放射增敏作用增强,剂量增强因子在 1.2-1.3 范围内。然而,50 nM 的 CX-5461 单独或与放射治疗联合使用不足以抑制 45S 转录。CX-5461 与放射治疗联合使用引起的细胞死亡机制是有丝分裂灾难,而不是细胞凋亡。CX-5461 抑制了修复和/或增强了辐射诱导的 DNA 双链断裂的初始水平。了解 CX-5461 诱导放射增敏的机制应该有助于 CX-5461/放射治疗联合应用于癌症治疗的潜在应用。